Bausch Health Companies Inc. (BHC) stock: key figures, P/E, revenue and dividend

Health Care · Canada · ISIN CA0717341071

Price
6.44 USD
Market cap
2.42 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Bausch Health Companies Inc. financials

Fiscal year2025
Revenue10.27 bn USD
Operating income1.81 bn USD
EBIT1.92 bn USD
Net income157.00 m USD
Diluted EPS – continuing operations0.42 USD

Full history since 1993, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Bausch Health Companies Inc.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.